Emergent BioSolutions (EBS) Deferred Taxes (2010 - 2026)

Emergent BioSolutions' Deferred Taxes history runs 17 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• On a quarterly basis, Deferred Taxes fell 124.19% year-over-year to -$4.5 million in Q1 2026; TTM through Mar 2026 was -$27.1 million, a 207.11% decrease from a year earlier, with the FY2025 full-year figure at -$4.0 million, up 27.27% from the prior year.
• Deferred Taxes fell to -$4.5 million in Q1 2026 per EBS's latest filing, from $1.5 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $22.9 million in Q3 2022 and bottomed at -$54.1 million in Q4 2022.
• The 5-year median for Deferred Taxes is -$400000.0 (2024), against an average of -$3.0 million.
• Across the five-year window, Deferred Taxes soared 502.63% in 2022 and tumbled 6850.0% in 2025, its largest moves.
• Year by year, Deferred Taxes stood at -$54.1 million in 2022, then surged by 90.39% to -$5.2 million in 2023, then jumped by 92.31% to -$400000.0 in 2024, then jumped by 475.0% to $1.5 million in 2025, then tumbled by 400.0% to -$4.5 million in 2026.
• Per Business Quant, the three latest EBS Deferred Taxes figures stand at -$4.5 million (Q1 2026), $1.5 million (Q4 2025), and -$10.2 million (Q3 2025).